Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
7.03M
-
Number of holders
-
30
-
Total 13F shares, excl. options
-
4.9M
-
Shares change
-
+4.64M
-
Total reported value, excl. options
-
$176M
-
Value change
-
+$167M
-
Number of buys
-
24
-
Number of sells
-
-3
-
Price
-
$36.02
Significant Holders of BRIGHT MINDS BIOSCIENCES INC. - Common Stock (DRUG) as of Q4 2024
31 filings reported holding DRUG - BRIGHT MINDS BIOSCIENCES INC. - Common Stock as of Q4 2024.
BRIGHT MINDS BIOSCIENCES INC. - Common Stock (DRUG) has 30 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.9M shares
of 7.03M outstanding shares and own 69.67% of the company stock.
Largest 10 shareholders include Cormorant Asset Management, LP (1.06M shares), JANUS HENDERSON GROUP PLC (509K shares), COMMODORE CAPITAL LP (500K shares), RA CAPITAL MANAGEMENT, L.P. (461K shares), Sio Capital Management, LLC (452K shares), PERCEPTIVE ADVISORS LLC (404K shares), Vivo Capital, LLC (252K shares), Logos Global Management LP (245K shares), MORGAN STANLEY (168K shares), and Ikarian Capital, LLC (152K shares).
This table shows the top 30 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.